Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles M. Brenner
University of Iowa, Department: Anesthesiology
Should you be removed from our database? Contact us at [email protected]. Read more below.
ChromaDex, Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Since Dr. Brenner has equity in and receives payment for consulting from the company whose product is being evaluated, and receives royalties from the company for the product being evaluated, bias or influence could be introduced into the research. Based on this analysis, we have determined that the interests could directly and significantly affect the design, conduct, or reporting of the PHS-funded research, or have the appearance of doing so.
Mechanistic Studies of the Natural Product Nicotinamide Riboside for Relief of Painful Sensory Neuropathy
Painful peripheral neuropathies are difficult to treat and a significant health care problem, particularly in the case of chemotherapy-induced peripheral neuropathies (CIPN) for which there are no evidence-based treatments. The finding that the natural product nicotinamide riboside, a vitamin B3 precursor of NAD+ that can correct mitochondrial dysfunction, ameliorates CIPN but not sensory neuropathy produced by frank nerve injury provides a unique opportunity to rigorously test several hypotheses concerning the mechanism of CIPN and other neuropathies. The results may lead to a better understanding of the mechanisms of CIPN, development of the first effective treatment for CIPN, and insight into why nicotinamide riboside will not be a universal treatment for all types of painful sensory neuropathies.
Filed on April 02, 2018.
Tell us what you know about Charles M. Brenner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Charles M. Brenner”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles M. Brenner | University of Iowa | Conflict of Interest | ChromaDex, Inc. | $20,000 - $39,999 |
| Charles M. Brenner | University of Iowa | Conflict of Interest | ChromaDex, Inc. | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.